Thisassaykitcontainsallthereagentsforcytolocalizationofhuman,p170topoIIusingimmunofluorescence. ThesystemisoptimizedforusewithFITCorRhodaminelabeledsecondaryantibodywithadherentcells. Themethodmayworkwithothercellsbesideshuman.Mouse,ratandmonkeycellswillcrossreactwithtopoIIantibody. Theantibodyisspecificforp170(topoIIalpha).
KitContents:
- 1
- Anti-topoII(p170)Antibody(TG2011-1). Thisisarabbitantibody(polyclonal)directedagainsttheC-Terminalregionofp170. Apeptidewasusedtoraisethisantiserum;theantibodyhasbeenimmunoaffinitypurified. Kitcontains100ulofantibody.
- 2
- Peptidereagent:(TG2011-2).Atotalof50ug(at2mg/ml)ofpeptideincluded.TheseqeunceistheC-terminal16aminoacidresiduesinp170.Thispeptideisinsodiumphosphatebuffer.
- 3
- DetailedManualofOperationThisprotocolwasdevelopedforusewithadherenttissueculturecells(HeLa,Vero,3T3,etc.). ApplicationsinvolvingsUSPensioncellculture,thinsectionsorhorserADIshperoxidasestainingwillrequiresomemodificationsworkedoutbytheinvestigator. ItisimportanttonotethatbecausetopoIIishighlyenrichedinchromosomes,aninternalcontrolisbuiltintothemethod;oneshouldseebrightlyfluorescentchromosomes(inmitoticcellsofcourse).
ControlsandImportantConsiderations
- 1
- AsnotedabovetopoisomeraseIIhasacharacteristicdistributionpatternincellsthatclearlyindicateswhethertheprocedureisworking.Ininterphasecells,thepatternofdistributionoftopoIIisalmosttotallynuclearandappearstobepunctiformorpin-pointinnature. ThesignalisclearlyamplifiedinmetaphasecellswhenchromosomesarevisIBLe. Thereshouldbeabouta5-10foldincreaseinfluorescentintensityinthelattercells.
- 2
- Thepeptidethatisincludedisanimportantcontrolreagent. IncubatingthecellswithpeptideplusprimarytopoIIantibodyshouldneutralizethefluorescentsignal.